Etanercept formulations stabilized with amino acids
The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A method of reducing formation of etanercept aggregates or fragments in a composition containing about 50 mg/ml etanercept, the method comprising combining about 50 mg/ml etanercept with about 100-120 mM glutamate in an aqueous pharmaceutical composition having a pH of about 6.0 to 6.6, wherein the aqueous pharmaceutical composition is free or essentially free of arginine, thereby preparing a stable aqueous etanercept composition.
2. The method of claim 1 , further comprising adding one or more additional components selected from: a buffer; a tonicity modifier, and an excipient to the aqueous pharmaceutical composition.
3. The method of claim 2 , wherein the aqueous pharmaceutical composition comprises less than 6 wt. % sucrose; optionally up to 100 mM NaCl; and about 1 to about 30 mM sodium phosphate buffer.
4. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by: an hydrophobic interaction chromatography (HIC) analysis at M 3 or T 2 or T 4 wherein the amount of the stable aqueous etanercept composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.
5. The method of claim 1 , wherein the stable aqueous etanercept composition has no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.
6. The method of claim 1 , wherein the stable aqueous etanercept composition comprises up to 3 wt. % sucrose.
7. The method of claim 6 , wherein the stable aqueous etanercept composition has no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm.
8. The method of claim 1 , wherein the stable aqueous etanercept composition further comprises less than 4 wt. % sucrose, and about 10 to 30 mM sodium phosphate buffer; and has a pH of about 6.3 to 6.5.
9. The method of claim 1 , wherein the stable aqueous etanercept composition comprises about 100 mM glutamate; less than 2 wt. % sucrose, about 100 mM NaCl; about 10-30 mM sodium phosphate buffer; and has a pH of about 6.3 to 6.5.
10. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by an HIC chromatogram, at M 3 or T 2 or T 4 , in which (i) peak 3 is absent, or the amount of the composition represented by peak 3 is less than or equal to 1 wt. % and (ii) peak 2 represents about 95 weight % of the composition or more; and peak 1 represents less than 3 wt. %.
11. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by an size exclusion chromatography (SEC) chromatogram, at M 3 or T 2 or T 4 , containing a monomer content of at least 95 wt % of the composition and fragment 3 content less than 5 wt. % of the composition.
12. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by SEC analysis at M 3 or T 2 or T 4 of: monomer content greater than about 90%; aggregates content of less than 3 wt %; and fragment 3 content less than 5 wt %.
13. The method of claim 1 , wherein the stable aqueous etanercept composition elicits long term storage stability as characterized by HIC analysis at M 3 or T 2 or T 4 , wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than 3 wt. %; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt. %; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than 20 wt. %.
14. A vial, syringe, or injector pen containing a stable aqueous etanercept composition comprising about 50 mg/ml etanercept and about 100-120 mM glutamate in an aqueous pharmaceutical composition having a pH of about 6.0 to 6.6, wherein the composition is free or essentially free of arginine.